MYC and ovarian cancer: Given the absence of enzymatic activity and the lack of surface domains specific for most pharmacological inhibitors, Myc is considered an “undruggable” protein [55], hence anti-Myc therapeutics might fall short of expectations in limiting ovarian cancers.